Merck & Co Inc
MRKToday
0.00%
5 Days
-1.09%
1 Month
+1.25%
6 Months
+5.28%
Year to Date
+21.96%
1 Year
+61.59%
Recent
Analysis
GSK plc Stock (GSK) Moved Down by 3.06% on Jul 17: Drivers Behind the Movement
• GSK shares face volatility due to ongoing Zantac litigation and potential settlement liabilities. • Industry pricing pressures and shifting institutional investment contribute to downward stock performance. • Uncertain clinical pipeline results and currency fluctuations impact the company's valuation and earnings.
Merck & Co Inc Stock (MRK) Moved Up by 3.24% on Jul 16: Drivers Behind the Movement
• Merck shares rose due to oncology pipeline progress and portfolio diversification. • Analysts increased price targets following strong vaccine and animal health performance. • Technical indicators show a neutral market signal with an RSI of 51.947.
Merck & Co Inc Stock (MRK) Moved Up by 3.05% on Jul 15: Key Drivers Unveiled
• Merck shares rose following positive oncology clinical data and robust pipeline developments. • Diversified growth in cardiovascular and immunology segments supports long-term revenue expectations. • Analysts revised forecasts upward, citing improved operational margins and disciplined capital allocation.
Merck & Co Inc Stock (MRK) Closed Up by 3.16% on Jul 2: What Signal Does It Send?
• Bank of America and Scotiabank raised price targets for Merck shares. • Strategic diversification and new drug assets mitigate concerns regarding the Keytruda patent cliff. • Merck continues upward momentum despite terminating an experimental Alzheimer’s drug trial.
Merck & Co Inc Stock (MRK) Moved Up by 4.04% on Jun 25: A Full Analysis
• FDA approved Keytruda and Trodelvy for treating advanced triple-negative breast cancer. • FDA granted expanded indication for the pediatric pneumococcal vaccine Capvaxive. • Management increased 2026 revenue and earnings-per-share guidance projections.
Merck & Co Inc Stock (MRK) Moved Up by 3.23% on Jun 23: Key Drivers Unveiled
• Merck’s tulisokibart met primary endpoints in Phase 3 ulcerative colitis trials. • Analysts project peak annual sales for tulisokibart could exceed five billion dollars. • Successful clinical results help Merck diversify revenue beyond its Keytruda franchise.
Merck & Co Inc's Score
Media Coverage
Analyst Rating
Merck & Co Inc Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Merck & Co Inc Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.52% |
| BlackRock Institutional Trust Company, N.A. | 5.51% |
| State Street Investment Management (US) | 4.86% |
| Wellington Management Company, LLP | 3.50% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 42.43% |
| Investment Advisor/Hedge Fund | 27.18% |
| Research Firm | 3.05% |
| Pension Fund | 2.68% |
Related Instruments
Popular Instruments
